RDHL

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Wall Street analysts forecast RDHL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDHL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Redhill Biopharma Ltd revenue for the last quarter amounts to 1.80M USD, decreased -90.21 % YoY.

Redhill Biopharma Ltd. EPS for the last quarter amounts to 0.01 USD, decreased -100.05 % YoY.

Redhill Biopharma Ltd (RDHL) has 35 emplpoyees as of December 18 2025.

Today RDHL has the market capitalization of 3.89M USD.